| Aug 12 |
Dare Bioscience GAAP EPS of $1.52 beats by $2.18, revenue of $22.43M
|
| Aug 12 |
Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update
|
| Aug 5 |
Daré Bioscience to Host Second Quarter 2024 Financial Results and Company Update Conference Call and Webcast on August 12, 2024
|
| Jul 19 |
Daré Bioscience regains compliance with Nasdaq's minimum bid price rule
|
| Jul 19 |
Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule
|
| Jun 27 |
Daré Bioscience announces reverse stock split
|
| Jun 27 |
Daré Bioscience Announces Reverse Stock Split
|
| Jun 24 |
Daré Bioscience Announces Publication in Obstetrics & Gynecology of Phase 2b Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder
|
